» Authors » Doris A E Parolin

Doris A E Parolin

Explore the profile of Doris A E Parolin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 126
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Restall I, Parolin D, Daneshmand M, Hanson J, Simard M, Fitzpatrick M, et al.
Cell Cycle . 2015 Jul; 14(18):2938-48. PMID: 26208522
Cellular senescence is a tumor suppressor mechanism where cells enter a permanent growth arrest following cellular stress. Oncogene-induced senescence (OIS) is induced in non-malignant cells following the expression of an...
2.
Baldwin R, Barrett G, Parolin D, Gillies J, Paget J, Lavictoire S, et al.
Mol Cancer . 2010 Sep; 9:233. PMID: 20815904
Background: Glioblastoma is one of the deadliest forms of cancer, in part because of its highly invasive nature. The tumor suppressor PTEN is frequently mutated in glioblastoma and is known...
3.
Gunaratnam L, Morley M, Franovic A, de Paulsen N, Mekhail K, Parolin D, et al.
J Biol Chem . 2003 Aug; 278(45):44966-74. PMID: 12944410
Bi-allelic-inactivating mutations of the VHL tumor suppressor gene are found in the majority of clear cell renal cell carcinomas (VHL(-/-) RCC). VHL(-/-) RCC cells overproduce hypoxia-inducible genes as a consequence...
4.
Daneshmand M, Parolin D, Hirte H, Major P, Goss G, Stewart D, et al.
Clin Cancer Res . 2003 Jul; 9(7):2457-64. PMID: 12855618
Purpose: Epidermal growth factor receptor (EGFR) appears to play an important role in the pathogenesis of colorectal cancer. We have performed a Phase I/II study of the EGFR tyrosine kinase...
5.
Lavictoire S, Parolin D, Klimowicz A, Kelly J, Lorimer I
J Biol Chem . 2002 Dec; 278(7):5292-9. PMID: 12471035
EGFRvIII is a mutant epidermal growth factor that promotes aggressive growth of glioblastomas. We made a plasmid that directed the expression of an EGFRvIII with three copies of the Flag...
6.
Lorimer I, Parolin D, Lavictoire S
Anticancer Res . 2002 May; 22(2A):623-31. PMID: 12014630
Background: Glioblastoma responds poorly to standard chemotherapy agents. The expression of a mutant, constitutively-active EGF receptor (EGFRvIII) is common in glioblastoma and contributes to chemotherapy resistance. We have assessed the...